Back in January I wrote about the FDA's attempt to convince drug makers that sell sleeping pills that contain the zolpidem active
ingredient – a list that includes Ambien – to lower current recommended
doses by half. See here. Today, AboutLawsuits is reporting that a group of doctors is backing the FDA’s view that new warnings
and lower dosages for Ambien and other sleep drugs are needed in a perspective article published last week in the New England Journal of Medicine. Go to AboutLawsuits for the details and links. The article is available here.
